Interleukin-1 alpha - Amgen/Roche
Alternative Names: Interleukin-1 alpha - ImmunexLatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Amgen
- Developer Amgen; Roche Palo Alto LLC
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin 1 alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hodgkin's disease; Malignant melanoma; Neutropenia; Radiation injuries; Thrombocytopenia
Most Recent Events
- 23 Feb 2000 No-Development-Reported for Hodgkin's disease in USA (Infusion)
- 23 Feb 2000 No-Development-Reported for Malignant melanoma in USA (Unknown route)
- 23 Feb 2000 No-Development-Reported for Neutropenia in USA (Parenteral)